The mean time to death of mice infected with Venezuelan equine encephalomyelitis (VEE) virus was increased 2 days by antithymocyte serum (ATS) treatment given 1 day before and 1 day after virus inoculation. Lymphocyte depletion has been described for several species during Venezuelan equine encephalomyelitis (VEE) virus infection (6, 15, 16) . During an investigation into immunological factors that might play a role in the pathogenicity of VEE virus infection of mice, the effect of antithymocyte serum (ATS) treatment was evaluated. The purpose of this investigation was to study selected lymphocyte populations associated with VEE virus pathogenicity in the laboratory mouse. ATS-induced lymphocyte changes were compared with VEE virusinduced lymphocyte changes. The effects of ATS on the time to death of mice infected with a lethal dose of VEE virus were determined. The levels of virus in various tissues and the role of passive homologous antibody were also measured in treated and untreated mice. Specific lymphocyte changes were examined by use of the surface immunoglobulin fluorescence technique to investigate a possible selective reduction in this subpopulation of mouse lymphocytes by VEE virus (1, 2, 7, 9, 11). The results are discussed in light of two possible mechanisms of action by the ATS.
Lymphocyte depletion has been described for several species during Venezuelan equine encephalomyelitis (VEE) virus infection (6, 15, 16) . During an investigation into immunological factors that might play a role in the pathogenicity of VEE virus infection of mice, the effect of antithymocyte serum (ATS) treatment was evaluated. The purpose of this investigation was to study selected lymphocyte populations associated with VEE virus pathogenicity in the laboratory mouse. ATS-induced lymphocyte changes were compared with VEE virusinduced lymphocyte changes. The effects of ATS on the time to death of mice infected with a lethal dose of VEE virus were determined. The levels of virus in various tissues and the role of passive homologous antibody were also measured in treated and untreated mice. Specific lymphocyte changes were examined by use of the surface immunoglobulin fluorescence technique to investigate a possible selective reduction in this subpopulation of mouse lymphocytes by VEE virus (1, 2, 7, 9, 11) . The results are discussed in light of two possible mechanisms of action by the ATS.
MATERIALS AND METHODS Experimental animals. Eight-to 10-week-old male inbred C3H HeJ mice (Jackson Memorial Labo- 6 and the latest on day 11. Mice treated with ATS had a mean time to death of 10.3 days, with all deaths occurring between days 9 and 13 inclusive. The two survival distributions were found to be significantly different (P s 0.001) by the Wilcoxon test for two samples. In general, ATS-treated mice exhibited symptoms of VEE virus infection for a longer time before death than did control mice. The levels of virus in the blood, spleen, and brain as determined by plaque titration in CEC cultures are shown in Fig. 2 . The virus levels are presented as plaque-forming units per gram of tissue or per milliliter of blood. Each point represents the mean of three mice. Although viremia levels were lower in the treated group during the first 2 days of infection, on day 3 these mice had the same amount of virus in the serum as controls had on day 2. The VEE virus levels found in brains of ATStreated mice were generally lower than the level found in VEE control mice. A similar pattern was seen in the spleens of these groups of mice. In the ATS-treated group the virus levels were delayed approximately 24 h and peak titers were 10-fold lower. Infected mice in both groups were tested for the time of development of neutralizing antibody and no differences were found. In both groups, neutralizing antibody appeared first on days 4 and 5.
Passive administration of hyperimmune mouse ascitic fluid on days 2, 3, or 4 did not significantly alter the mean time to death in either ATS-treated or control mice. When antibody was given 24 h after VEE, 20% of the mice survived, and the remaining mice in both ATS Effect of ATS on spleen. The effect of ATS treatment alone on the spleen of C3H HeJ mice is shown in Fig. 3 Effect of ATS on peripheral blood. The ,*~effect of ATS on total leukocyte count, absolute lymphocyte number, and absolute neutrophil number was determined. The normal value data collected in our laboratory were in agreement with those data published several years earlier for this mouse strain (14) . A marked 4 5 leukopenia and lymphopenia was observed throughout the period of investigation. An increase in neutrophils was also evident on days virus in the 3, 4, 5, and 6. Fig. 4 . Control mice that received only VEE virus on day 0 demonstrated significant decreases in spleen weight on days 2 through 5. Mice inoculated with VEE virus and treated with ATS on days -1 and 1 showed a significant reduction in spleen weight only on day 4. In Fig. 5 , the effect of ATS treatment on the splenic lymphocyte population of VEE-inoculated mice is shown. The percentage of splenic B lymphocytes was determined by immunoglobulin staining. The total number of splenic lymphocytes was plotted as a percentage of normal values. The percentage of B lymphocytes was determined by counting the number of fluorescing cells and calculating the percentage on the basis of the total number of glass-nonadhering mononuclear cells per spleen. The relative number or percentage of splenic B lymphocytes increased during VEE virus infection. When ATS treatment was given in conjunction with VEE virus infection, a greater reduction in the total splenic lymphocyte population and a greater relative increase in B lymphocytes were observed. During this time, the total number of splenic lymphocytes decreased whereas the absolute number of B lymphocytes changed only slightly.
Controls. NRS did not demonstrate any significant effect on either the death pattern of mice infected with VEE virus or on any of the other parameters evaluated. Neither the adsorbed NRS nor ATS showed any significant antiviral antibody. The 80% plaque reduction titer for both sera was less than 1:5. The effectiveness of the ATS, established by the commercial producer, was confirmed by determinations made in our laboratory. Immunoelectrophoresis of conjugated anti-mouse globulin confirmed the presence of anti-mouse IgG, IgM, and IgA. The specificity of lymphocyte staining was confirmed by blocking experiments with unlabeled anti-mouse globulin. Preincubation with anti-horse globulin did not block mouse antiglobulin fluorescence.
DISCUSSION
Changes in the relative concentrations of T and B lymphocyte populations have been reported for bacterial infections, viral infections, and neoplastic diseases (2, 5, 8) . There is, however, little direct information concerning the role of T and B lymphocytes in acute viral infections.
Mice infected with VEE virus have been shown to develop a generalized necrosis of the myeloid and lymphoid tissues as well as encephalomyelitis (15) . The lesions in the spleen were characterized by empty sinusoids, congestion in the pulp cords, and necrosis of the Malpighian follicles. Recent work has shown that, whereas the mantle layer around the follicles contains bone marrow-derived (B) lymphocytes, the periarterial lymphatic sheaths contain thymus-derived (T) lymphocytes (4). It has also been noted that ATS treatment of mice resulted in a depletion of lymphocytes in the periarterial sheaths of the spleen when mice were treated for a 30-day period after birth (13) .
Our results demonstrated that ATS treatment of VEE virus-infected mice significantly prolonged the mean time to death. Viral assays demonstrated that the pattern of infection is the same for both treated and untreated mice; however, treated mice showed approximately a 1-day delay in the course of the disease. The ATS treatment apparently delayed VEE virus replication by approximately 24 h and perhaps reduced the total quantity of virus produced. When the dosage of ATS was continued on days 3, 5, and 7 after VEE virus inoculation, the mean time to death was not consistently increased, although in some experiments the higher doses of ATS did further prolong the survival 1 additional day.
The relative number of splenic B lymphocytes increased during VEE infection, and ATS alone caused a similar effect. When ATS treatment was given in conjunction with VEE virus infection, the effect was additive and there was an even greater increase in the relative number of B lymphocytes. The total number of splenic lymphocytes decreased whereas the absolute number of B lymphocytes changed only slightly. Thus, the relative increase in B lymphocytes in these groups of animals reflects a selective depletion of the nonimmunoglobulinbearing lymphocyte population (T cells) of the spleen. There are several possible explanations of these data. The prolongation of life by ATS treatment could be considered as evidence that death from VEE infection in the mouse is mediated by immunopathology. Our results indicated that this is not the case; instead, the ATS depressed or altered cells associated with the normal pathogenesis and replication of VEE virus infection in the mouse. Additionally, ATS and VEE may share a common target since the inoculation of VEE virus into an ATS-immunosuppressed mouse resulted in lower levels of virus production. Rabinowitz and Adler (10) showed T cell-mediated immunity that may appear to conflict with these data. However, we used the virulent Trinidad strain of VEE virus whereas Rabinowitz and Adler (10) 
